Aa
new info on new kind of tx?
Does anyone have any information on some new drugs coming out in the future for hep c patients?
Hi fretboard;I just replied to nygirl17 and then realized there are 2 mikes on this thread.Which Mike do you wish to reply?Thanks.Micheall
Hey Mike, hope you're doing well. Weren't you you in a clinical trial for incivek? Sorry to hear about your relapse, was it an actual relapse or what exactly happened? If you already told the forum just throw me a link. There are many new drugs currently in trials and still being developed by drug companies here in California and some outside of Cali. Either way, every day I hear about something coming down the pike so it won't be long. I would think you would want to take a break though after going through a few months of tx. good luck
Mike I can't remember what stage you are but dont think it was too high. If I had time to wait I'd see what was going to happen with the all orals.......why put yourself through interferon again if you dont have to. Of course, we have no timeline on the new meds but they certainly are promising and we have every hope that they pan out!
I read this and followed the website you provided.I copied the 15 page report and will give it to my dr.We are not forgotten.There is more research out there than expected.Thank you for the info.
My hepatologist is excited about the new orals.
They could be available in a few years or you could look into a clinical trail if your interested.
The future of hep c treatment looks bright.
They could be available in a few years or you could look into a clinical trail if your interested.
The future of hep c treatment looks bright.
Discontinuation of Dosing
Patients with inadequate viral response are unlikely to achieve SVR, and may develop treatment-emergent resistance substitutions [see Microbiology (12.4)].
12.4 Microbiology
Persistence of Resistance-Associated Substitutions
Persistence of telaprevir-resistant NS3 amino acid substitutions has been observed following treatment failure. Of a combined 255 treatment-naïve and previously treated subjects from Trials 108, 111, and C216 in whom telaprevir-resistant variants had emerged during treatment, 103 (40%) had detectable resistant variants by population sequencing at end of trial (follow-up range 2-70 weeks, median 45 weeks) and results for loss of variants were similar across the three trials. In the combined trials, 46% of the telaprevir-resistant substitutions in subtype 1a and 16% of the substitutions in subtype 1b were still detected by the end of trial: 29% of V36, 16% of T54, 38% of R155, 14% of A156, and 44% of V36M+R155K variants were detected at the end of trial.
In a 3-year follow-up trial of 56 treatment-naïve and prior treatment-failure subjects who did not achieve SVR with a telaprevir regimen in a Phase 2 trial and had telaprevir-resistant variants after treatment failure, variants were detected by population sequencing in 11% (6/56) of subjects (median follow-up of 25 months). Telaprevir-resistant variants V36L/M, T54S, and R155K were detectable (present at greater than 25% of the viral population) in some subjects at 24 months. By 36 months, V36M, T54A/S, and A156N/S/T variants had fallen below the level of detection by population sequencing in all subjects. At 36 months, 3% of the subject isolates that had the R155K variant still had detectable R155K variants by population sequencing.
The lack of detection of a substitution based on a population-based assay does not necessarily indicate the substitution has declined to the pre-treatment level. The long-term clinical impact of the emergence or persistence of detectable INCIVEK resistance-associated substitutions is unknown. No data are available regarding INCIVEK efficacy among patients who were previously exposed to INCIVEK, or who previously failed treatment with an INCIVEK-containing regimen.
Perhaps reading what info years of research has proven would be helpful
Mike as far as new drugs available in the future, things look very promising, here is link to advocates journals, she has posted lots of INFO on the new drugs as they were presented at the 2012 ESLD meeting
http://www.medhelp.org/user_journals/index/1739543?personal_page_id=2242526
Patients with inadequate viral response are unlikely to achieve SVR, and may develop treatment-emergent resistance substitutions [see Microbiology (12.4)].
12.4 Microbiology
Persistence of Resistance-Associated Substitutions
Persistence of telaprevir-resistant NS3 amino acid substitutions has been observed following treatment failure. Of a combined 255 treatment-naïve and previously treated subjects from Trials 108, 111, and C216 in whom telaprevir-resistant variants had emerged during treatment, 103 (40%) had detectable resistant variants by population sequencing at end of trial (follow-up range 2-70 weeks, median 45 weeks) and results for loss of variants were similar across the three trials. In the combined trials, 46% of the telaprevir-resistant substitutions in subtype 1a and 16% of the substitutions in subtype 1b were still detected by the end of trial: 29% of V36, 16% of T54, 38% of R155, 14% of A156, and 44% of V36M+R155K variants were detected at the end of trial.
In a 3-year follow-up trial of 56 treatment-naïve and prior treatment-failure subjects who did not achieve SVR with a telaprevir regimen in a Phase 2 trial and had telaprevir-resistant variants after treatment failure, variants were detected by population sequencing in 11% (6/56) of subjects (median follow-up of 25 months). Telaprevir-resistant variants V36L/M, T54S, and R155K were detectable (present at greater than 25% of the viral population) in some subjects at 24 months. By 36 months, V36M, T54A/S, and A156N/S/T variants had fallen below the level of detection by population sequencing in all subjects. At 36 months, 3% of the subject isolates that had the R155K variant still had detectable R155K variants by population sequencing.
The lack of detection of a substitution based on a population-based assay does not necessarily indicate the substitution has declined to the pre-treatment level. The long-term clinical impact of the emergence or persistence of detectable INCIVEK resistance-associated substitutions is unknown. No data are available regarding INCIVEK efficacy among patients who were previously exposed to INCIVEK, or who previously failed treatment with an INCIVEK-containing regimen.
Perhaps reading what info years of research has proven would be helpful
Mike as far as new drugs available in the future, things look very promising, here is link to advocates journals, she has posted lots of INFO on the new drugs as they were presented at the 2012 ESLD meeting
http://www.medhelp.org/user_journals/index/1739543?personal_page_id=2242526
Have an Answer?
You are reading content posted in the Hepatitis C Community
Learn about this treatable virus.
Getting tested for this viral infection.
3 key steps to getting on treatment.
4 steps to getting on therapy.
What you need to know about Hep C drugs.
How the drugs might affect you.
These tips may up your chances of a cure.
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
